期刊
TRANSLATIONAL CANCER RESEARCH
卷 8, 期 2, 页码 473-482出版社
AME PUBL CO
DOI: 10.21037/tcr.2019.03.01
关键词
Rapamycin (RAPA); NKG2D ligand; acute myeloid leukemia (AML); STAT3; immune escape
类别
资金
- Youth Talent S&T Project of the Changzhou Commission of Health [QN201821]
Background: The constitutive activation of the mammalian target of rapamycin (mTOR) is involved in the pathogenesis of many cancers. Rapamycin (RAPA), a specific inhibitor of mTOR, has been applied to the clinical treatment of tumors, and its anti-leukemia effect has also been confirmed. Methods: We detected apoptosis and the NKG2D ligands expression in acute myeloid leukemia (AML) cells using flow cytometry and investigated the cytotoxicity of AML cells that had been co-cultured with natural killer (NK) cells using CFSE staining. We evaluated the signal pathways with a western blot assay. Results: In this study, we found that RAPA can significantly inhibit the proliferation of AML cells. Further studies showed that the use of RAPA alone reduced the expression of NKG2D ligands on the membranes of HL-60 and THP-1 AML cells. Also, RAPA blocked the upregulation of the NKG2D ligand when AML cells were cultured with the demethylation drug dedtabine (DAC). We found that RAPA decreased the expression of the NKG2D ligands by inducing the STAT3 phosphorylation of AML cells. Conolusions: The discovery of this mechanism might further optimize the clinical use of RAPA for the treatment of AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据